Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 831
- Registration Number
- NCT00150176
40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 77
- Registration Number
- NCT00145509
Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 468
- Registration Number
- NCT00145496
12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 326
- Registration Number
- NCT00145470
A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 180
- Registration Number
- NCT00142558
9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 504
- Registration Number
- NCT00143182
Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 120
- Registration Number
- NCT00140959
ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 367
- Registration Number
- NCT00140907
Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 97
- Registration Number
- NCT00140985
A Study to Determine the Effect of Montelukast Sodium as an Episode Modifier in the Treatment of Infrequent Episodic Asthma in Children (0476-165)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 220
- Registration Number
- NCT00140881
© Copyright 2024. All Rights Reserved by MedPath